Results from the PCCTC-managed Abiraterone, Olaparib, or Abiraterone + Olaparib in First-line mCRPC with DNA Repair Defects (BRCAAway) Study Published in Clinical Cancer Research

The data from this trial supports an advantage of upfront combination therapy with ARP-I + PARP-I versus either single-agent alone in patients with metastatic castration resistant prostate cancer and qualifying HRR mutations.